Share on LinkedInShare on LinkedIn

ARTICLE · 26 DECEMBER 2025

Federal Circuit Clarifies That Only Identical Inventors Avoid Becoming Prior Art Under Pre-AIA 102(e)

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., No. 25-1210 (Fed. Cir. Oct. 30, 2025), the Federal Circuit affirmed a PTAB decision invalidating...

United StatesIntellectual Property

In Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., No. 25-1210 (Fed. Cir. Oct. 30, 2025), the Federal Circuit affirmed a PTAB decision invalidating two Merck patents directed to methods for treating multiple sclerosis, U.S. Patent Nos. 7,713,947 and 8,377,903.

Hopewell filed IPR petitions challenging claims of both of Merck's asserted patents as obvious over Bodor in view of Stelmasiak. Merck argued that the Bodor reference, which was published two months before the priority date of Merck's applications, was not prior art because De Luca, one of the inventors of the asserted patents, had made an inventive contribution to the Bodor application, despite not being listed as an inventor. The PTAB disagreed, finding (1) that Merck failed to produce sufficient evidence of De Luca's contribution, and (2) that Bodor would nonetheless qualify as prior art.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from